Fc Receptors | Critical regulators of antibody biology and therapy
Host: Faculty of Medical and Human Sciences
About the event:
Professor Mark Cragg is Professor in Experimental Cancer Biology from the University of Southampton.
Mark is interested in all aspects of how therapeutics result in tumour regression and is focused on three main types – antibodies, chemotherapy and kinase inhibitors with the aim of understanding how these therapeutics function to delete tumour cells and how they might be augmented.
In particular he is interested in how monoclonal antibodies interact with Fc gamma receptors to achieve their therapeutic activities. Over the last decade, he has investigated many different therapeutic reagents such as rituximab, bexxar, imatinib, gefitinib, cetuximab and tarceva and has been involved in the development of next generation reagents such as ofatumumab and obinutuzumab.
Please email email@example.com (+44(0)161 306 0114) to register your attendance for this free event.
Role: Professor in Experimental Cancer Biology
Organisation: University of Southampton
Travel and Contact Information
Holt Major Seminar Room